326 related articles for article (PubMed ID: 24613816)
1. Final results of local-regional control and late toxicity of RTOG 9003: a randomized trial of altered fractionation radiation for locally advanced head and neck cancer.
Beitler JJ; Zhang Q; Fu KK; Trotti A; Spencer SA; Jones CU; Garden AS; Shenouda G; Harris J; Ang KK
Int J Radiat Oncol Biol Phys; 2014 May; 89(1):13-20. PubMed ID: 24613816
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase I/II trial of two variants of accelerated fractionated radiotherapy regimens for advanced head and neck cancer: results of RTOG 88-09.
Fu KK; Clery M; Ang KK; Byhardt RW; Maor MH; Beitler JJ
Int J Radiat Oncol Biol Phys; 1995 Jun; 32(3):589-97. PubMed ID: 7790243
[TBL] [Abstract][Full Text] [Related]
3. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003.
Fu KK; Pajak TF; Trotti A; Jones CU; Spencer SA; Phillips TL; Garden AS; Ridge JA; Cooper JS; Ang KK
Int J Radiat Oncol Biol Phys; 2000 Aug; 48(1):7-16. PubMed ID: 10924966
[TBL] [Abstract][Full Text] [Related]
4. Randomized trial of hyperfractionation versus conventional fractionation in T2 squamous cell carcinoma of the vocal cord (RTOG 9512).
Trotti A; Zhang Q; Bentzen SM; Emami B; Hammond ME; Jones CU; Morrison WH; Sagar SM; Ridge JA; Fu KK; Ang KK
Int J Radiat Oncol Biol Phys; 2014 Aug; 89(5):958-963. PubMed ID: 25035199
[TBL] [Abstract][Full Text] [Related]
5. Value of intensity-modulated radiotherapy in Stage IV head-and-neck squamous cell carcinoma.
Dirix P; Nuyts S
Int J Radiat Oncol Biol Phys; 2010 Dec; 78(5):1373-80. PubMed ID: 20362402
[TBL] [Abstract][Full Text] [Related]
6. Hyperfractionated accelerated radiation therapy (HART) of 70.6 Gy with concurrent 5-FU/Mitomycin C is superior to HART of 77.6 Gy alone in locally advanced head and neck cancer: long-term results of the ARO 95-06 randomized phase III trial.
Budach V; Stromberger C; Poettgen C; Baumann M; Budach W; Grabenbauer G; Marnitz S; Olze H; Wernecke KD; Ghadjar P
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):916-24. PubMed ID: 25670541
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity.
Nguyen-Tan PF; Zhang Q; Ang KK; Weber RS; Rosenthal DI; Soulieres D; Kim H; Silverman C; Raben A; Galloway TJ; Fortin A; Gore E; Westra WH; Chung CH; Jordan RC; Gillison ML; List M; Le QT
J Clin Oncol; 2014 Dec; 32(34):3858-66. PubMed ID: 25366680
[TBL] [Abstract][Full Text] [Related]
8. Comparison of conventional fractionation (five fractions per week) and altered fractionation (six fractions per week) in stage I and II squamous cell carcinoma of oropharynx: An institutional study.
Poddar J; Sharma AD; Kunikullaya SU; Neema JP
Indian J Cancer; 2017; 54(1):6-10. PubMed ID: 29199652
[TBL] [Abstract][Full Text] [Related]
9. Final Report of a Prospective Randomized Trial to Evaluate the Dose-Response Relationship for Postoperative Radiation Therapy and Pathologic Risk Groups in Patients With Head and Neck Cancer.
Rosenthal DI; Mohamed ASR; Garden AS; Morrison WH; El-Naggar AK; Kamal M; Weber RS; Fuller CD; Peters LJ
Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1002-1011. PubMed ID: 28721881
[TBL] [Abstract][Full Text] [Related]
10. Potential doubling time and clinical outcome in head and neck squamous cell carcinoma treated with 70 GY in 7 weeks.
Bourhis J; Dendale R; Hill C; Bosq J; Janot F; Attal P; Fortin A; Marandas P; Schwaab G; Wibault P; Malaise EP; Bobin S; Luboinski B; Eschwege F; Wilson G
Int J Radiat Oncol Biol Phys; 1996 Jun; 35(3):471-6. PubMed ID: 8655369
[TBL] [Abstract][Full Text] [Related]
11. Altered and conventional fractionated radiotherapy in locoregional control and survival of patients with squamous cell carcinoma of the larynx, oropharynx, and hypopharynx.
Krstevska V; Crvenkova S
Croat Med J; 2006 Feb; 47(1):42-52. PubMed ID: 16489696
[TBL] [Abstract][Full Text] [Related]
12. P105 as a prognostic indicator in patients irradiated for locally advanced head-and-neck cancer: a clinical/laboratory correlative analysis of RTOG-9003.
Hammond E; Berkey BA; Fu KK; Trotti A; Meredith RF; Jones CU; Byhardt R; Horwitz EM; Ang KK
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):683-92. PubMed ID: 14529772
[TBL] [Abstract][Full Text] [Related]
13. Accelerated hyperfractionated irradiation with concomitant boost for stage II laryngeal cancer and locally advanced head and neck cancer.
Ishii K; Tashiro M; Hosono M; Fukuda H; Takada Y; Kondo S; Inoue Y; Iguchi H; Kusuki M; Yamane H
Acta Otolaryngol Suppl; 2004 Oct; (554):62-6. PubMed ID: 15513514
[TBL] [Abstract][Full Text] [Related]
14. A dose escalation study with intensity modulated radiation therapy (IMRT) in T2N0, T2N1, T3N0 squamous cell carcinomas (SCC) of the oropharynx, larynx and hypopharynx using a simultaneous integrated boost (SIB) approach.
Leclerc M; Maingon P; Hamoir M; Dalban C; Calais G; Nuyts S; Serre A; Grégoire V
Radiother Oncol; 2013 Mar; 106(3):333-40. PubMed ID: 23541643
[TBL] [Abstract][Full Text] [Related]
15. Comparison of hyperfractionation and conventional fractionation radiotherapy with concurrent docetaxel, cisplatin and 5-fluorouracil (TPF) chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Katori H; Tsukuda M; Watai K
Cancer Chemother Pharmacol; 2007 Aug; 60(3):399-406. PubMed ID: 17096160
[TBL] [Abstract][Full Text] [Related]
16. Whole-Field Sequential Intensity-Modulated Radiotherapy for Local-Regional Advanced Head-and-Neck Squamous Cell Carcinoma.
Refaat T; Choi M; Thomas TO; Bacchus I; Agulnik M; Pelzer HJ; Mellott AL; Rademaker AW; Liu D; Sathiaseelan V; Mittal BB
Am J Clin Oncol; 2015 Dec; 38(6):588-94. PubMed ID: 24136140
[TBL] [Abstract][Full Text] [Related]
17. Radiation-free weekend rescued! Continuous accelerated irradiation of 7-days per week is equal to accelerated fractionation with concomitant boost of 7 fractions in 5-days per week: report on phase 3 clinical trial in head-and-neck cancer patients.
Skladowski K; Hutnik M; Wygoda A; Golen M; Pilecki B; Przeorek W; Rutkowski T; Lukaszczyk-Widel B; Heyda A; Suwinski R; Tarnawski R; Maciejewski B
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):741-6. PubMed ID: 22836063
[TBL] [Abstract][Full Text] [Related]
18. Accelerated versus conventional fractionated postoperative radiotherapy for advanced head and neck cancer: results of a multicenter Phase III study.
Sanguineti G; Richetti A; Bignardi M; Corvo' R; Gabriele P; Sormani MP; Antognoni P
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):762-71. PubMed ID: 15708255
[TBL] [Abstract][Full Text] [Related]
19. Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial.
Kuhnt T; Becker A; Pigorsch S; Pelz T; Bloching M; Passmann M; Lotterer E; Hänsgen G; Dunst J
Strahlenther Onkol; 2003 Oct; 179(10):673-81. PubMed ID: 14566475
[TBL] [Abstract][Full Text] [Related]
20. Accelerated radiation therapy for locally advanced squamous cell carcinomas of the oral cavity and oropharynx selected according to tumor cell kinetics--a phase II multicenter study.
Antognoni P; Bignardi M; Cazzaniga LF; Poli AM; Richetti A; Bossi A; Rampello G; Barbera F; Soatti C; Bardelli D; Giordano M; Danova M
Int J Radiat Oncol Biol Phys; 1996 Dec; 36(5):1137-45. PubMed ID: 8985036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
